MHRA Confirms Registration of Avacta's AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback